IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
- Conditions
- Familial Chylomicronemia Syndrome
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05185843
- Locations
- 🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦Centre Hospitalier Universite de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada
🇺🇸Diabetes/Lipid Management & Research Center, Huntington Beach, California, United States
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
- Conditions
- Phlebotomy Dependent Polycythemia Vera
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05143957
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇵🇱Wojewódzki Szpital Specjalistyczny Sp. z o.o., Słupsk, Poland
🇵🇱MICS Centrum Medyczne Toruń, Toruń, Poland
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT05139810
- Locations
- 🇬🇧
Ionis Investigative Site, London, United Kingdom
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- Familial Chylomicronemia Syndrome
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05130450
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇺🇸University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States
🇺🇸IDS Central, Philadelphia, Pennsylvania, United States
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT05127226
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of North Carolina at Chapel Hill School of Medicine, Carrboro, North Carolina, United States
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 617
- Registration Number
- NCT05079919
- Locations
- 🇺🇸
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
🇿🇦Dr Jan Engelbrecht and Ass. Inc, Cape Town, Western Cape, South Africa
🇳🇱Albert Schweitzer ziekenhuis, Dordrecht, Netherlands
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Conditions
- Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05071300
- Locations
- 🇫🇷
Hôpital de la Timone, Marseille, France
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Son Llàtzer, Palma De Mallorca, Spain
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04934891
- Locations
- 🇨🇦
BioPharma Services, Inc., Toronto, Ontario, Canada
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT04932512
- Locations
- 🇺🇸
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
🇺🇸Covenant Metabolic Specialists, LLC, Sarasota, Florida, United States
🇺🇸Louisiana Research Center, LLC, Shreveport, Louisiana, United States
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04849741
- Locations
- 🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇺🇸Children's Hospital of Atlanta, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States